cremophor EL

solvent for Althesin & Propanidid implicated as possible cause of similar adverse effects polyethoxylated castor oil; RN given refers to cpd with unknown MF; see also records for cremophor & cremophor A

Also Known As:

Networked: 222 relevant articles (11 outcomes, 30 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Fong, Wing-Ping: 4 articles (10/2011 - 12/2007)
2.	Ng, Dennis K P: 4 articles (10/2011 - 12/2007)
3.	Sparreboom, Alex: 4 articles (01/2006 - 06/2003)
4.	Beijnen, J H: 4 articles (11/2001 - 07/2000)
5.	Colson, Yolonda L: 3 articles (05/2015 - 02/2009)
6.	Grinstaff, Mark W: 3 articles (05/2015 - 02/2009)
7.	Liu, Rong: 3 articles (05/2015 - 02/2009)
8.	Luo, Juntao: 3 articles (04/2015 - 06/2010)
9.	Wei, Yuquan: 3 articles (04/2015 - 01/2012)
10.	Gelderblom, Hans: 3 articles (05/2009 - 06/2003)

Related Diseases

1.	Neoplasms (Cancer) 10/01/2009 - "PTX-30W reduced the number of metastatic nodules and tumor volume significantly more than did conventional PTX dissolved in Cremophor EL (PTX-Cre), and prolonged the survival time (P < 0.05). " 06/19/2006 - "This formulation was designed to overcome vehicle toxicity associated with the traditional Cremophor EL-based formulation and to provide the added advantages of prolonged systemic circulation time and selective targeting of the FR, which is frequently overexpressed on epithelial cancer cells. " 03/10/2006 - "Finally, PTX was less toxic to the tumor-bearing mice when formulated in HGC nanoparticles than when formulated with Cremophor EL." 11/01/2004 - "Animals that received a single-dose intratumoral injection of Tx-NPs-Tf (Tx dose= 4 mg/kg) demonstrated complete tumor regression and greater survival rate than those that received either Tx-NPs or Tx-Cremophor EL formulation. " 08/01/2002 - "The in vitro cytotoxicity of the copolymers was evaluated on EMT-6 mouse mammary tumor cells in comparison to Cremophor EL (CRM). "
2.	Breast Neoplasms (Breast Cancer) 09/01/2011 - "We report the first case of Cremophor EL-induced cutaneous lupus erythematosus-like reaction in a 40-year-old female undergoing treatment for breast cancer. " 11/01/2009 - "When administered orally to rats bearing chemically induced breast cancer, nanoparticles were equally effective/better than intravenous paclitaxel in cremophor EL at 50% lower dose. " 08/01/2009 - "Delayed seizure associated with paclitaxel-Cremophor el in a patient with early-stage breast cancer." 10/01/2005 - "In vitro and in vivo data on breast cancer cells and xenografts in nude mice indicate that paclitaxel nanosomes are less toxic and much more effective than paclitaxel in Cremophor EL (Taxol). " 03/01/2005 - "Paclitaxel in a novel formulation containing less Cremophor EL as first-line therapy for advanced breast cancer: a phase II trial."
3.	Hypersensitivity (Allergy) 01/01/2022 - "However, Cremophor EL has been shown to have serious adverse side effects, such as hypersensitivity reactions and neurotoxicity. " 03/01/2019 - "The polymeric PTX nanoparticles free from the cremophor EL will help in eliminating the shortcomings of the existing delivery system as cremophor EL causes serious allergic reactions to the subjects after intravenous use. " 05/01/2015 - "It was withdrawn from clinical practice because of hypersensitivity to Cremophor EL. " 09/20/2010 - "Because of its low solubility, it is formulated in high concentration in Cremophor EL(®) which induces hypersensitivity reactions. " 01/01/2009 - "Many adverse reactions to the PTX formulation have been reported because of the presence of Cremophor EL, including hypersensitivity reactions, nephrotoxicity, and neurotoxicity. "
4.	Neoplasm Metastasis (Metastasis) 01/01/2016 - "In this study, we developed Lx2-32c-loaded polymeric micelles (Lx2-32c-PMs) with small size and investigated their antitumor efficacy against tumor growth and metastasis on 4T1 murine breast cancer cell line with Cremophor EL-based Lx2-32c solution as the control. "
5.	Body Weight (Weight, Body) 11/01/1996 - "The rats were injected subcutaneously with 50 mg/kg (body weight) of CsA or with equal volume of the vehicle, Cremophor-EL, for 7 consecutive days. " 09/01/2001 - "The decrease in body weight was greater for paclitaxel in Cremophor EL than for liposomal paclitaxel, but hematological toxicity was similar. " 03/01/1993 - "A dose of 50 mg/kg (body weight) of cyclosporine and an equal volume of vehicle (cremophor-EL) were injected into the rats subcutaneously for 7 or 11 consecutive days. " 12/01/2008 - "These combined features resulted in the following advantages over paclitaxel/Cremophor EL: greater tumor targeting (16-times higher and more sustained concentration in omental tumors), lower toxicity to intestinal crypts and less body weight loss, greater therapeutic efficacy (longer survival and higher cure rate), and greater convenience (less frequent dosing). " 09/01/2001 - "Paclitaxel in liposomes or Cremophor EL was administered to rats at doses of 20 or 40 mg/kg. Body weight and absolute neutrophil count were determined daily. "

Related Drugs and Biologics

1.	Paclitaxel (Taxol)
2.	Solutions
3.	130-nm albumin-bound paclitaxel
4.	Ethanol (Ethyl Alcohol)
5.	Micelles
6.	Albumin-Bound Paclitaxel
7.	Verapamil (Calan)
8.	Lipoproteins (Lipoprotein)
9.	Etoposide (VP 16)
10.	Albumins

Related Therapies and Procedures

1.	Therapeutics
2.	Injections
3.	Drug Therapy (Chemotherapy)
4.	Aftercare (After-Treatment)
5.	Intravenous Administration